DexCom, Inc. with ticker code (DXCM) now have 16 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 245 and 185 and has a mean target at 211. Given that the stocks previous close was at 223.92 this indicates there is a potential downside of -5.8%. The 50 day MA is 185.09 while the 200 day moving average is 158.45. The market capitalisation for the company is $20,929m. You can visit the company’s website by visiting: http://www.dexcom.com
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.